文献速递肝病消化道出血

全身炎症严重程度是急性失代偿期肝硬化患者发生慢加急性肝衰竭和出血的主要预测因素

Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis.
PubMed 文献 · J Hepatol · 2022-09-21

前瞻性研究纳入169例急性失代偿期肝硬化住院患者,进行广泛止血谱分析并随访1年。结果发现急性失代偿期肝硬化较对照者存在更明显的血浆高凝状态(ETP 871 vs 750 vs 605 nmol/L/min,p<0.0001),但纤溶激活无差异。全身炎症严重程度(CRP)而非凝血病,是慢加急性肝衰竭和出血的主要预测因素;基于CLIF-C AD、CRP和Child-Pugh的Padua模型可准确识别慢加急性肝衰竭高风险患者(AUROC 0.857;95% CI 0.798-0.915),并在独立双中心欧洲队列(N=301)中得到验证。

要点

  • 急性失代偿期肝硬化患者存在更明显的血浆高凝状态,但纤溶激活与对照无差异。
  • CRP、CLIF-C AD和Child-Pugh独立关联慢加急性肝衰竭,Padua模型AUROC 0.857。
  • CRP和进展至慢加急性肝衰竭(而非基线凝血病)与出血相关;CRP和PAI-1>50 ng/ml与血栓形成相关。

核心结论

  • 炎症严重程度而非凝血病是急性失代偿期肝硬化患者发生慢加急性肝衰竭和出血的最重要预测因素。
  • Padua模型可用于识别有慢加急性肝衰竭风险的急性失代偿期肝硬化患者。

研究设计与样本

  • 前瞻性研究,纳入169例急性失代偿期肝硬化住院患者(中位MELD评分20;CLIF-C AD 54)。
  • 研究分两部分:第1部分比较急性失代偿期肝硬化与稳定失代偿期及代偿期肝硬化对照者的止血指标;第2部分前瞻性随访1年,探讨慢加急性肝衰竭及出血/血栓形成的预测因素。
  • Padua模型的预后价值在独立的双中心欧洲队列(N=301)中得到验证。

主要发现

  • 与对照者相比,急性失代偿期肝硬化与更明显的血浆高凝状态相关(ETP:871 vs 750 vs 605 nmol/L/min;p<0.0001),纤溶激活无差异。
  • 随访期间55例发生慢加急性肝衰竭;CLIF-C AD、CRP和Child-Pugh独立关联慢加急性肝衰竭。
  • Padua模型(联合CLIF-C AD、CRP和Child-Pugh)识别慢加急性肝衰竭高风险患者的AUROC为0.857(95% CI 0.798-0.915),敏感性74.5%,特异性83.3%。
  • 出血11例,与CRP和进展至慢加急性肝衰竭相关,而与基线凝血病无关;血栓形成14例,与CRP和抗纤溶因子PAI-1>50 ng/ml相关。

关键数值与推荐

  • Padua模型预测慢加急性肝衰竭的AUROC为0.857(95% CI 0.798-0.915),敏感性74.5%,特异性83.3%。
  • ETP在急性失代偿期肝硬化、稳定失代偿期肝硬化和代偿期肝硬化分别为871、750和605 nmol/L/min(p<0.0001)。
  • CRP和抗纤溶因子PAI-1>50 ng/ml与血栓形成相关。

临床怎么用

  • 作者认为,基于CRP和肝病评分开发的简易预测模型若经独立研究验证,可用于临床实践,帮助医生识别疾病进展和死亡风险较高的失代偿期肝硬化患者(即考虑加快肝移植评估者)。
  • 作者指出,止血指标改变的评估无助于识别有疾病进展风险的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hypercoagulability and hypofibrinolysis in acutely decompensated cirrhosis (AD) may be implicated in disease progression and haemostatic complications. We conducted a prospective study to: (1) characterise haemostatic alterations in AD; (2) evaluate whether such alterations can predict acute-on-chronic liver failure (ACLF) and bleeding/thrombosis. METHODS: Hospitalised individuals with AD were prospectively recruited and underwent an extensive haemostatic profiling including coagulation factors, thrombomodulin-modified thrombin generation assay with evaluation of endogenous thrombin potential (ETP; marker for plasmatic hypercoagulability), fibrinolytic factors, and plasmin-antiplasmin complex (fibrinolysis activation marker). Inflammation severity was assessed by C-reactive protein (CRP). In part 1 of the study, we compared haemostasis in AD vs. controls (stable decompensated and compensated cirrhosis). In part 2 of the study, we prospectively followed individuals with AD for 1 year and investigated predictors of ACLF and bleeding/thrombosis. RESULTS: A total of 169 individuals with AD were recruited (median model for end-stage liver disease score 20; CLIF-C AD 54). Compared with controls, AD was associated with more pronounced hypercoagulability (ETP: 871 vs. 750 vs. 605 nmol/L per min; p <0.0001), without differences in fibrinolysis activation. During follow-up, 55 individuals developed ACLF. CLIF-C AD, CRP, and Child-Pugh were independently associated with ACLF. A predictive model combining these variables (Padua model) accurately identified individuals at higher risk of ACLF (AUROC 0.857; 95% CI 0.798-0.915; sensitivity 74.5%, specificity 83.3%). Notably, CRP and progression to ACLF, but not baseline coagulopathy, were associated with bleeding (n = 11); CRP and antifibrinolytic factor PAI-1 >50 ng/ml were associated with thrombosis (n = 14). The prognostic value of the Padua model was validated in an independent, bicentric European cohort (N = 301). CONCLUSIONS: Inflammation severity, and not coagulopathy, is the most important predictor of ACLF and bleeding in AD. The Padua model can be used to identify individuals with AD at risk of ACLF. IMPACT AND IMPLICATIONS: A better understanding of haemostasis in individuals with acutely decompensated cirrhosis may help to identify those at higher risk of progression and complications. In this prospective study, we found no significant association between alterations of haemostasis and cirrhosis progression, indicating that the assessment of haemostatic alterations is not useful to identify those at risk. However, we found that C-reactive protein (a simple blood test that reflects severity of inflammation) and severity of chronic liver disease itself (as assessed by specific scores) were associated with cirrhosis progression and development of bleeding complications. Therefore, we developed a simple predictive model - based on C-reactive protein and liver disease scores - that, if validated by independent studies, could be used in clinical practice to assist physicians in identifying individuals with decompensated cirrhosis at higher risk of disease progression and death (i.e. in whom to consider an expedited evaluation for liver transplantation).

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zanetto A, Pelizzaro F, Campello E, et al. Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis. J Hepatol. 2022. PMID: 36150575. doi:10.1016/j.jhep.2022.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。